{"retracted":false,"update":{"timestamp":1424736000000,"doi":"10.1212/wnl.0000000000001255","type":"correction"},"doi":"10.1212/wnl.0000000000000355","journal":"Neurology","publisher":"Ovid Technologies (Wolters Kluwer Health)","title":"MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study"}
